Press Releases

3 Dec 2018

Arizona Patients Successfully Receive the World’s First Bioconvertible ...

BTG plc (LSE: BTG), the global healthcare company, today announced the first patients outside of a clinical trial have been successfully implanted with the BTG Sentry device – the world’s first bioconvertible IVC filter. The BTG Sentry filter is designed to provide protection from Pulmonary Embolism (PE) for the period of transient risk and then bioconvert to leave a patent, unobstructed IVC lumen, eliminating the need to retrieve and addressing the typical filter-related complications associated with conventional IVC filters.

20 Nov 2018

Recommended Cash Offer for BTG plc by Boston Scientific Corporation

Recommended Cash Offer for BTG plc by Boston Scientific Corporation

13 Nov 2018

BTG plc: Interim Results 2018

BTG plc (LSE: BTG), the global healthcare company, today announces its Interim Results for the six months ended 30 September 2018.

6 Nov 2018

EKOS™ Control Unit 4.0 simplifies treatment of blood clots

BTG plc (LSE: BTG), the global healthcare company, announced today that the first EKOS™ CU 4.0 units have been shipped from BTG’s facility in Bothell (Washington, US) to Europe, where full commercial launch will begin. New features of the EKOS™ CU 4.0 include an interactive colour touchscreen, a built-in battery and separate ports for managing two EKOS™ devices simultaneously.

4 Oct 2018

BTG plc: close period update

Good first half performance, updating full year sales growth guidance BTG plc (LSE: BTG), the global healthcare company, provides the following update for the six months ended 30 September 2018.

4 Oct 2018

BTG plc: Directorate change

BTG plc (LSE: BTG), the global healthcare company, announces that Garry Watts has informed the Board that he wishes to retire as Chairman and Non-executive Director of the Company. The Board has commenced a process to appoint a successor to Mr Watts, who will continue as Chairman until 31 December 2018.

26 Sep 2018

BTG Announces Replacement Policy for Expired CroFab®

BTG plc (LSE: BTG) today announced a policy for replacement of expired vials of CroFab® Crotalidae Polyvalent Immune Fab (Ovine), allowing customers to return the product for replacement up to 90 days after expiration. This change goes into effect immediately, and provides CroFab®customers with a process for replacing their expired product at no charge. CroFab® is the only available FDA-approved product for the management of all North American pit viper envenomations in adult and pediatric patients.1

13 Sep 2018

FDA Approves CroFab® Product Improvements

Updated label describes extended shelf life and removal of mercury

9 Aug 2018

BTG receives not-approvable letter from the US FDA for ELEVAIR™

BTG plc (LSE: BTG), the global specialist healthcare company, today announces that PneumRx® has received confirmation from the US Food and Drug Administration (FDA) that the Premarket Approval (PMA) application for its ELEVAIR™ Endobronchial Coil System for the treatment of people with severe emphysema is not approvable. This follows the FDA Advisory Panel’s recommendation in June 2018 not to approve ELEVAIR™. BTG is reviewing options and will provide an update in due course.

18 Jul 2018

BTG plc: Annual General Meeting

BTG plc (LSE: BTG), the global specialist healthcare company, provides the following update ahead of its Annual General Meeting, which is being held today at 10.30am at the offices of Stephenson Harwood LLP, 1 Finsbury Circus, London EC2M 7SH.